

Essential tremor: diagnosis and management

Vicki Shanker



Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Correspondence to: Vickilynn.shanker@mountsinai.org

Additional material is published online only. To view please visit the journal online.

Cite this as: *BMJ* 2019;366:l4485 <http://dx.doi.org/10.1136/bmj.l4485>

Series explanation: State of the Art Reviews are commissioned on the basis of their relevance to academics and specialists in the US and internationally. For this reason they are written predominantly by US authors.

ABSTRACT

Essential tremor is one of the most common movement disorders in adults and can affect both children and adults. An updated consensus statement in 2018 redefined essential tremor as an isolated action tremor present in bilateral upper extremities for at least three years. Tremor may also be present in other locations, commonly the neck or the vocal cords. Patients with additional neurologic symptoms are now categorized as “essential tremor plus.” Additional clinical features associated with the condition include but are not limited to cognitive impairment, psychiatric disorders, and hearing loss. When treatment is needed, propranolol and primidone are considered first line treatments. Patients who are severely affected are often offered deep brain stimulation. Although the ventral intermediate nucleus of the thalamus is the traditional surgical target, the caudal zona incerta is also being studied as a possible superior alternative. Magnetic resonance imaging guided high intensity focused ultrasound is a newer surgical alternative that may be ideal for patients with substantial medical comorbidities. Current research explores novel oral treatments, chemodenervation, and noninvasive neuromodulation for treatment of essential tremor.

Introduction

Essential tremor is a syndrome defined as a “bilateral upper extremity action tremor” and is among the most common movement disorders in adults.¹ As life expectancy increases, the prevalence of essential tremor increases, and the number of patients with essential tremor presenting in the office for treatment is thus growing. The historical practice of grouping all action tremors together may partially explain both the difficulties in identifying genetic causes and patients’ variable responses to treatment.

Decades after their initial study, propranolol and primidone remain the first line oral drugs for essential tremor. However, only about half of the patients taking these drugs have a significant reduction in the amplitude of tremor.² Little is known about the long term efficacy of treatments, as few trials have had long term follow-up. Very few interventions have class I evidence for their efficacy. The emergence of surgical alternatives for treatment offers new options for the most severely affected patients. In the past decade, novel treatments ranging from chemodenervation to noninvasive neuromodulation bring new excitement into the field. The goal of this review is to summarize the clinical features associated with the condition, the recommended changes in classification, and the current treatment options.

Epidemiology

Worldwide, the crude prevalence rates of essential tremor in adults range from 0.4% to 6%.^{3,4} Essential

tremor affects approximately 1% of the population and 4-5% of people aged over 65 years.^{5,6} Studies suggest a bimodal age of onset.⁷ A clinical study of 978 patients with probable or definite essential tremor identified an early onset group with age 24 years or less and an older onset group with age 46 years or above.⁸ A retrospective chart review of 211 children found that the onset can be as early as birth, but the mean onset age was 9.7 (SD 5.6) years.⁹ Essential tremor in children has a male predominance that ranges from 1.6:1 to 3:1. Although adult onset essential tremor is not thought to have a sex imbalance, a population study of 2117 older adults also found a significant male predominance in the 46 patients with essential tremor ($\chi^2=5.0$, $P=0.03$).³

Sources and selection criteria

Comprehensive search strategies covered the topics of diagnosis, medical and surgical management, and drug treatment in essential tremor. A combination of subject headers and keywords was designed in conjunction with a medical librarian. The searches were executed in the Medline (PubMed) and Embase (Ovid) databases from database inception through 25 February 2019. No date filters were used. Non-English language papers were excluded. Non-systematic reviews were weighted lower than systematic reviews. Studies were prioritized by quality and size. Case reports were excluded. Complete search queries in both databases are reported in the web appendix.

Additional searching was conducted on an as needed basis.

Clinical manifestations

Tremor

Limb tremor

The onset and progression of essential tremor are insidious. Arm involvement is kinetic tremor with or without postural tremor affecting both arms. The tremor is a rhythmic oscillation of agonist and antagonist muscles, typically at a frequency between 8 Hz and 12 Hz. In earlier studies, the diagnosis was made on the basis of the presence of either postural or kinetic tremor. However, the amplitude of the kinetic tremor is the most prominent component of limb tremor in essential tremor.¹⁰ In a cross sectional study of 369 patients with essential tremor, kinetic tremor was more severe than postural tremor in around 95%.¹¹ Although both upper limbs are involved in essential tremor, mild-moderate asymmetry in the amplitude of tremor is common¹²; the postural tremors in the two hands are out of phase, which dampens the tremor when a patient holds items with both hands.¹³

Tremor at rest can occur in patients with longstanding disease. The prevalence of rest tremor in essential tremor was studied in 831 people from four distinct populations. Prevalence ranged from 2% in a population based setting to 46% in a brain bank study.¹⁴ Pathologic study of seven patients with essential tremor who had rest tremor confirmed the lack of parkinsonian pathology.¹⁵

Intention tremor, the increased amplitude of tremor as a target is neared, is not present at disease onset but is seen later in some patients with essential tremor; its emergence is associated with disease duration.¹⁶ The prevalence of intention tremor in patients with essential tremor is around 44%. It may be associated with head and trunk tremor.¹⁷ A clinical-epidemiologic study of 117 patients with essential tremor found that 40% had intention tremor in the arms. Approximately 27% (95% confidence interval 20% to 36%) of 128 patients with essential tremor enrolled in a clinical-epidemiologic study had intention tremor in one or both legs.¹⁸ A case-control study reported kinetic leg tremor in 44% of 63 patients with essential tremor compared with 14% of controls ($P<0.001$); tremor was at least moderate in amplitude in about 14% of patients compared with 2% of controls ($P=0.008$).¹⁹

Increasing amplitude of tremor or development of intention tremor may affect writing. A case-control study ($n=200$) reported macrographic handwriting in some patients with essential tremor.²⁰ Spiral drawings in the office can assess these changes. Although disease progression from year to year may be subtle, prospective studies ($n=116$, $n=83$) showed detectable changes in spiral drawings approximately five years later.^{21,22} With disease progression, tremor can interfere with activities of daily functioning such as eating and grooming. Tremors in both dominant and non-dominant hands can cause functional

disability.²³ Older patients have more rapid progression of tremor.

Head tremor

Many patients with essential tremor develop head tremor. Head tremor is typically a late clinical manifestation of the disease; the presence of isolated head tremor should raise suspicion for an alternate diagnosis (cervical dystonia).^{24,25}

Multivariate analysis in a cross sectional clinical-epidemiologic study of 363 patients with essential tremor reported that head tremor, present in 140 (39%) patients was associated with age (odds ratio 1.04, 95% confidence interval 1.02 to 1.06) but not disease duration. Comparing patients with at least 10 years of disease, 2/27 (7%) patients under 40 years of age had tremor compared with 121/283 (43%) over 60.²⁶ Head tremor is more common in women.^{26,27} A clinical-pathologic study ($n=137$) found women to be at high risk for developing head tremor independent of disease duration (odds ratio 6.5, 2.2 to 19.0). In a video review, 102/386 (26%) patients with essential tremor had head tremor,²⁸ 70 (69%) of whom had an exacerbation during or immediately after a phonation task in which patients were asked to sustain “ahh” or “eee” for 10-15 seconds; monitoring neck movements during phonation tasks is a helpful clinical pearl to assess the presence of head tremor. Head tremor will most commonly dissipate when the patient is supine, which can help in distinguishing essential tremor from other disease entities in which a resting head tremor is seen.²⁹ Aside from an action induced tremor, patients with head tremor may have an intention component that can be seen when the patient moves the head forward to sip from a cup.³⁰ A review of videotaped patients with essential tremor found that almost half of patients with head tremor (19/39) were unaware of its presence.³¹ A study of 51 essential tremor patients with head tremor defined movements as “no-no” (horizontal), “yes-yes” (vertical), or mixed directional.³² Patients with “no-no” tremor generally have short disease duration; mixed and “yes-yes” tremors are associated with older age ($P=0.004$) and longer disease duration ($P=0.018$). Patients with mixed direction tremor were reportedly more likely to have a continuous neck tremor and greater severity of tremor.

Chin/jaw tremor

Chin or jaw tremor is uncommon in essential tremor. An estimated 1-2% of patients per year with essential tremor develop head or jaw tremor. The incidence rate for either tremor is 10-20% in a 10 year period.³³ The presence of jaw tremor increases with disease severity, with a reported prevalence of 7.5% (95% confidence interval 3.9% to 14.2%) in a population study, 10.1% (6.8% to 14.7%) in a tertiary care center, and 18% (12.3% to 25.5%) in a brain bank of deceased patients with severe essential tremor ($P=0.03$).³⁴ Jaw tremor in essential tremor never appears solely at rest.³⁴ It is most prominent in posture and may be seen during sustained phonation

or manifest as a kinetic tremor when the patient is talking. If rest tremor in the jaw is present, the amplitude is never as prominent as during posture or action. Conversely, jaw tremor in Parkinson's disease is prominent at rest and typically disappears with talking. The presence of jaw tremor is associated with older age of onset, greater severity of hand tremor, and rest tremor in the hands. Patients with jaw tremor are more likely to have hand or voice tremor than are those without jaw tremor.

Vocal tremor

Vocal tremor is a clinical manifestation of essential tremor. Older studies included patients who would not meet modern definitions of essential tremor owing to lack of arm involvement. This is concerning, as isolated vocal tremor is typically due to an alternate diagnosis (dystonia). It is more common in women and appears most frequently in the seventh decade. Women are more likely than men to manifest vocal symptoms.

Vocal changes are often described as "weak," "unstable," "shaky," or "hoarse." A descriptive clinical cohort study (n=34) reported that patients commonly complained of challenges maintaining voice volume and increased phonatory effort.³⁵ Patients with voice tremor are aware of the tremor and often express concern that changes in their voice will be misinterpreted as an anxious or upset emotion. Some patients report alcohol responsive improvements in voice.

Laryngoscopy of essential tremor patients with vocal tremor shows an entrained, oscillatory motion of several anatomic structures during sustained phonation. Many patients have oscillatory movements during quiet respiration. Tremor can involve muscles of the palate, pharynx, tongue, and other articulatory muscles in addition to the larynx. This involvement does not distinguish vocal tremor of essential tremor from spasmodic dysphonia. A cross sectional study of 19 ear, nose, and throat patients with either essential tremor or dystonic tremor found that dystonic patients were more likely to have reduction of tremor in the palate (P=0.02), pharynx (P=0.038), and larynx (P=0.002) when using a higher "falsetto" pitch.³⁶

Rating scales are commonly used in research. In the office, clinicians can use rating scales to assist in diagnosis and to provide an objective measure of the severity, progression, and response to treatment of tremor. The Movement Disorder Society established a task force to review available scales. The Washington Heights-Inwood Genetic Study of Essential Tremor Rating Scale version 1 was recommended for screening. Five rating scales were recommended for assessing severity of tremor: the Fahn-Tolosa-Marin Tremor Rating Scale, the Bain and Findley Clinical Tremor Rating Scale, the Bain and Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential Tremor Rating Scale, and the Tremor Research Group Essential Tremor Rating Assessment Scale.³⁷

Disease process

Essential tremor is a progressive condition. Despite progression, less than 10% of 335 patients with long disease duration in a cross sectional clinical-epidemiologic study developed significant disability.³⁸ Predictors of clinical progression include disease duration, asymmetrical tremor, and an isolated limb involvement at onset.³⁹ Patients with older age of onset may have a more rapid disease course.⁸ Pediatric populations are similar to adult populations as they present with bilateral kinetic arm tremor. Some children also develop voice, head, neck, and leg tremor. Children can also have rest tremor. Unlike adults, children rarely report impaired activities due to tremor.⁹

Alcohol responsiveness

In approximately 50% of patients with essential tremor, symptoms improve with alcohol consumption.⁴⁰ Responsiveness to alcohol is not pathognomonic for essential tremor. In a cross sectional multicenter trial, 29.3% (369/1258) of patients with isolated dystonia reported improvement with alcohol.⁴¹ Patients with earlier onset are more likely to report alcohol responsiveness.⁸ No historical features can help to predict whether a patient will be responsive to alcohol. Despite concerns of increased alcoholism in the essential tremor population, studies have not supported this.⁴²⁻⁴⁴ A test for alcohol responsiveness showed a peak effect at 45 minutes after consumption in 10 patients, with persistent benefit in the initial 90 minutes.⁴⁵ It is common for tremor to rebound with increased intensity after more than three hours.⁴⁰

Balance difficulties/gait impairment

Some patients with essential tremor report balance difficulties. Studies have tested balance by assessing tandem gait and using posturography.⁴⁶⁻⁴⁸ Patients with essential tremor perform worse than age matched controls in balance testing. Posturography suggests that balance impairments are present in all patients with essential tremor. Younger patients may be able to use compensatory mechanisms to perform better in clinical tests.

Hearing loss

A population based sample reported hearing impairment in 39% (96/248) of people with essential tremor compared with 29.4% (1371/4669) of controls (P=0.002). Those with impairment were 30% more likely to have essential tremor (odds ratio 1.3, 1.01 to 1.7; P=0.04).⁴⁹ A large case-control study with 248 essential tremor patients and 4669 controls found that a significantly greater number of essential tremor patients wore hearing aids compared with patients with Parkinson's disease of similar age and controls (16.8% v 1.6% v 0.8%). Audiology testing shows high frequency sensorineural hearing loss in essential tremor patients.⁵⁰ The average hearing thresholds at 250-500 Hz are higher in patients with essential tremor.⁵¹

Olfactory changes

Reports of olfactory dysfunction in essential tremor are mixed, which may be due to the heterogeneous causes of the condition. A case-control study of 87 patients with essential tremor and 92 controls reported a mild, but significant, impairment on the University of Pennsylvania Smell Identification Test (UPSIT). This finding was independent of cognitive impairment as assessed by the mini-mental state examination.⁵² However, other studies report normal UPSIT scores in patients with essential tremor.⁵³ A study matching essential tremor patients, Parkinson's disease patients, and controls found impairment in Parkinson's disease patients but no difference between the essential tremor patients and controls.⁵⁴ Additionally, in a separate study, essential tremor patients with rest tremor and no signs of parkinsonism had normal UPSIT scores, similar to essential tremor patients without rest tremor.⁵⁵ These findings suggest that the UPSIT may be one tool to help clinicians distinguish Parkinson's disease from essential tremor clinically.

Eye findings

Patients with essential tremor may have changes in oculomotor movements. A case-control study of 60 essential tremor patients matched with controls found that patients with essential tremor were more likely to have interruptions with square wave jerks during fixation ($P < 0.001$). In addition, reflexive saccades (saccades triggered exogenously by the introduction of a peripheral stimulus or by the withdrawal of a fixation stimulus) are affected in essential tremor. Latencies and velocities of reflexive saccades were increased in patients with essential tremor.⁵⁶ A case-control study of 50 patients with essential tremor reported that the latency of reflexive saccades was associated with severity of tremor. Additionally, an increased incidence of dysmetria was seen during reflexive saccades in patients with more severe disease.⁵⁷

Psychiatric symptoms

Several studies have explored the personality profile and psychiatric comorbidities of essential tremor. A case-control study used the 100 item Tridimensional Personality Questionnaire to assess personality traits; patients with essential tremor scored higher in areas of harm avoidance, worrying/pessimism, and fatigue/asthenia. Because data were collected in affected patients, whether these personality traits emerged before or after onset of tremor is unknown.⁵⁸ Almost half of 106 patients with essential tremor from a population sample reported embarrassment, which is an independent predictor of increased drug dosage (odds ratio 1.86; $P = 0.01$).⁵⁹

Depression and anxiety are significantly increased in patients with essential tremor compared with controls and can be similar to what is seen in Parkinson's disease.⁶⁰⁻⁶² This is true in younger and older populations.⁶³ Patients may experience anxiety as an internal tremor.⁶⁴ A cross sectional case-control

study ($n = 100$) showed that, in addition to higher rates of depression (44% v 8%, $P = 0.009$) and anxiety (66% v 18%, $P = 0.009$), patients with essential tremor also have increased sleep disturbances (46% v 8%, $P < 0.001$) and fatigue (30% v 8%, $P = 0.009$) compared with healthy controls. Additionally, the study found that patients with essential tremor had increased pain severity as measured on the Brief Pain Inventory-Severity (1.9 (SD 2.3) v 0.6 (1.2); $P = 0.001$) compared with controls and more interference from pain as measured on the Brief Pain Inventory-Interference (2.0 (2.9) v 0.5 (1.2); $P = 0.001$).⁶⁵

Cognitive symptoms

Although early descriptions of essential tremor did not identify cognitive impairments, pre-surgical neuropsychological assessments identified impairments, sparking further studies. The impairment is typically mild and is often not recognized by the patient.⁶⁶⁻⁶⁷ A 2012 literature review of cognition in essential tremor reported that mild executive dysfunction was a consistent finding in studies. Impairments of attention and working memory were commonly seen. A 2017 cross sectional analysis of 128 older patients with essential tremor found that both amnesic and non-amnesic mild cognitive impairment (MCI) subtypes were represented ($n = 24$); amnesic MCI, single and multi-domain, represented about 70% ($n = 17$) of cases.⁶⁸ Multi-domain amnesic MCI was the most common subtype ($n = 13$; 54%) Five neuropsychological tests that are sensitive to mild cognitive deficits in patients with essential tremor (as defined by a Clinical Dementia Rating of 0.5) are the California Verbal Learning Test II Total Recall, Logical Memory II, Verbal-Paired Associates I, category Switching Fluency, and Color-Word Inhibition.⁶⁹

Signs of other movement disorders

A small portion of patients with essential tremor have clinical findings that are features of other movement disorders. An examination of 678 patients with essential tremor reported the co-existence of Parkinson's disease (~6%), dystonia (~7%), and myoclonus (1.8%) in this population.⁷⁰ A 600 person case-control study found that, compared with healthy controls, patients with Parkinson's disease had higher odds of developing essential tremor (odds ratio 5.43, 1.16 to 25.39). Patients with Parkinson's disease were five to 10 times more likely to develop essential tremor.⁷¹ Many studies have explored the association of Parkinson's disease and essential tremor through study of the clinical features, imaging, and genetics. What, if any, factors influence the development of essential tremor or Parkinson's disease in the presence of the other is still uncertain.⁷²

Diagnosis

Essential tremor is a clinical diagnosis. The office history and examination are the sole components needed for diagnosis. The clinician asks about

tremor during different modalities and the effect on activities of daily living. Symptoms described above are queried. Alcohol responsiveness and family history can be helpful clues, but neither feature is specific to essential tremor. Patients with dystonia can have alcohol responsiveness and a family history of tremor. Approximately 50% of patients with essential tremor have a family history. Accuracy of this history is not reliable, as a family study showed that probands poorly identified tremor in family members, missing tremor in affected members and recalling tremor in family members who did not have symptoms. The age of onset of essential tremor may be lower in patients with a family history.⁷³⁻⁷⁴

A study of several bedside tests performed in 154 patients (42 essential tremor, 112 controls), including assessments using arm extension, finger-to-nose movements, spiral drawing, pouring water, drinking water, and using a spoon, showed variability of the tremor in different settings. Because of performance variability, asking patients to perform several tasks in the office may lead to a more accurate assessment of tremor.⁷⁵ A video is provided with this review to show essential tremor when pouring and writing, and figure 1 shows spiral drawings. Voice and neck tremor are also shown.

A complete neurologic examination is needed. The tremor of essential tremor can be confused in the office with Parkinson's disease and dystonic tremor. Several clinical pearls can help to guide the clinician to the correct diagnosis. A cross sectional study including 50 patients with essential tremor and 50 with Parkinson's disease found that during arm extension, essential tremor is more likely an extension-flexion at the wrist rather than movements at the metacarpal-phalangeal or phalangeal joints.⁷⁶ In addition, more than 25% of patients with essential tremor showed an intention tremor in finger-to-nose testing, whereas the presence of intention tremor in Parkinson's disease was about 4% ($P < 0.001$). In writing and Archimedes spiral samples, the axis of essential tremor is commonly in the 8-2 o'clock in right handed drawing and 10-4 o'clock in left handed drawings (see video). This is seen in script writing,

especially with vertical letters such as "h," "l," and "p."⁷⁷ This can help to differentiate essential tremor from dystonia, in which this axis is uncommon. On examination, up to 20% of patients with essential tremor will have a unidirectional, non-oscillatory head jerk ("head snap") during the finger-to-nose examination as the finger nears the nose. A cross sectional study of 50 patients with Parkinson's disease and 50 with essential tremor found that the "head snap" was seen in some essential tremor cases (20%) but no Parkinson's disease cases.⁷⁸ Table 1 lists some pearls for differentiating essential tremor from Parkinson's disease and dystonia.

A magnetic resonance imaging (MRI) scan of the brain could be considered to exclude a secondary source of onset of tremor, especially when additional neurologic symptoms are present. No guidelines are available for the use of functional imaging (¹²³I-FP-CIT SPECT (DaTscan)) or accelerometry. In the US, the DaTscan has approval from the Food and Drug Administration for use as an adjunctive evaluation tool to differentiate essential tremor from a tremor due to a parkinsonian syndrome. The development of consumer grade accelerometry, which can be helpful in distinguishing essential tremor from Parkinson's disease tremor, may emerge as a viable clinical diagnostic tool as the technology becomes more accessible. Spiral drawings can be performed directly on digital tablets capable of analyzing the characteristics and severity of tremor.⁹⁰⁻⁹² Accessibility and cost represent a barrier to the use of imaging and other technology.

Classification of essential tremor

The variability in clinical presentations and disease course, the inconsistency in pathologic study findings, and the lack of diagnostic electrophysiologic and radiologic findings argue against essential tremor being a single disorder.⁹³ In 2018 an updated consensus statement from the task force on tremor of the International Parkinson and Movement Disorder Society redefined essential tremor as a syndrome. The classification was an attempt to recognize the heterogeneity of these symptoms, which are unified



Fig 1 | This sample of an Archimedes spiral and continuous loop drawing performed by a patient with essential tremor demonstrates a unidirectional tremor axis

Table 1 | Clues to distinguish essential tremor from other tremor disorders

Feature	Essential tremor	Parkinson tremor	Dystonic tremor
Activating condition on presentation of limb tremor ¹	Action tremor	Rest tremor	Action tremor
Common upper limb presentation at onset ⁷⁹	Bilateral; mild asymmetry; wrist involvement; no finger involvement; flexion/extension movement; no directionality	Unilateral or bilateral; marked asymmetry; wrist involvement; finger involvement; rotary movement; no directionality	Unilateral or bilateral; marked asymmetry; elbow, wrist, or finger involvement + directionality
Other areas frequently involved in tremor	Neck; voice	Mouth/tongue; jaw; leg	Neck; voice; jaw
Common tremor activation	Kinetic tremor amplitude \geq postural; posture in wing may be greater than posture with arm extension ⁸⁰	Rest tremor \geq postural tremor; when moving from rest to posture, there is often a pause before recurrence of tremor	Kinetic >> postural
Common alleviating factors	Rest; alcohol	Activity	Sensory trick (decreased tremor with light touch) ⁸¹ ; null point (position where tremor decreases/remits)
Limb tremor: handwriting/spirals ⁸²	Normal size or macrographic; pen pressure normal or mildly increased; 2-3 o'clock axis on right hand spirals; 10-12 o'clock axis on left hand spirals ⁷⁷	Micrographic, decrementing ⁸³⁻⁸⁵ ; pen pressure reduced ⁸⁶ ; unilateral axis on spirals	Variable quality: can be cramped and tight; pen pressure increased ⁸⁷ ; multidirectional axis on spirals
Intention tremor ⁷⁶	May be present, especially after longer disease duration	Not usually present	Not usually present
Associated limb symptoms/signs	None	Bradykinesia; rigidity	Tightness and posturing in limb; sensory trick ⁸¹
Voice (when affected) ^{36 88}	Intensity fluctuations with perception of increased effort	Hypophonic; patient perceives speaking as normal	Strained, strangled, or breathy quality
Neck tremor	No pain or muscle hypertrophy; often anosognosia to tremor ³¹ ; dissipates when supine ²⁹	Rare; persists when supine	Associated with pain and muscle hypertrophy ⁸⁹ ; patient aware of neck tremor; persists when supine, if not in null position

only by the presence of action tremor in the arms.¹ In the new criteria, essential tremor is defined as an isolated tremor syndrome with only action tremor present for at least three years. The presence of tremor in other locations such as the legs, head, or voice is allowed. The tremor is identified as an isolated postural or kinetic tremor if it has been present for less than three years. No signs of other neurologic disease such as dystonia, ataxia, or parkinsonism are allowed to be designated as essential tremor.

A second disorder, labeled “essential tremor plus,” maintains the criteria of essential tremor but allows for the presence of other neurologic signs such as dystonia or cognitive impairment. Exclusion criteria for essential tremor and essential tremor plus include the presence of isolated focal tremors in the head or voice, orthostatic tremor with a frequency above 12 Hz, task and position specific tremors, and a sudden onset of symptoms with a stepwise deterioration. The consensus statement did not define the range and quality of these additional “soft” neurologic signs. This has generated new concerns and questions. For example, a patient who develops a rest tremor is classified as essential tremor plus; although the presence of this tremor could be a parkinsonian sign, it could also be the evolution of essential tremor.⁹⁴ One study reassigned patients with essential tremor to the newly defined classifications; challenges interpreting cerebellar symptoms and possible dystonic posturing were reported.⁹⁵

Treatment of essential tremor

Many patients report symptoms of tremor as mild and opt to delay intervention. Because tremor often improves with alcohol consumption, patients may choose to have an alcoholic drink before social situations. When symptoms are socially

bothersome or interfere with activities of daily living, patients often seek medical intervention. Available interventions can only treat the symptoms.

Drug treatment

Oral drugs are the first line of treatment. Few advances in the development of oral drugs used in the treatment of essential tremor have been made over the past two decades. Many of the landmark trials of the first line drugs were done in the 1970s and 1980s under older definitions of the disease that could have included patients with enhanced physiologic tremor. These trials tended to be small, often containing fewer than 20-30 patients in a treatment arm. Most of these trials measured efficacy only for short periods of time. The true long term response to treatment for most drugs used in essential tremor is unknown. Because essential tremor is a syndrome with many causes, the fact that response to available treatments is variable is not surprising. Some drugs had benefit in small trials, but evidence is insufficient to make recommendations. At the time of this review, both the American Academy of Neurology (AAN) and the Italian Movement Disorders Association (IMDA) had produced guidelines for the management of essential tremor.⁹⁶⁻⁹⁸ Only recommended drugs will be highlighted in this review. Table 2 summarizes the main recommended treatments used in essential tremor.

Existing drugs for essential tremor are suboptimal. Many patients do not respond to them, and those who do may not have a significant improvement in their daily life. A study reviewing response to treatment of 528 patients in three different research settings reported that approximately one in three patients discontinued drugs prescribed for essential tremor.² Polytherapy should be considered when monotherapy provides a partial response but is insufficient. The

side effect profile of drugs used in essential tremor may limit both monotherapy and polytherapy.

β blockers

Propranolol is one of two recommended first line therapies for essential tremor. Propranolol is given in divided doses, three times daily. Table 3 summarizes a sample of studies with level 1 evidence assessing the response of limb tremor to propranolol. The table

highlights the small sample size, short periods of assessment, and variability or lack of definition of essential tremor stated in the studies. Head tremor and voice tremor do not objectively respond to chronic propranolol therapy.^{114 115}

Small studies indicate that long acting propranolol is as effective as the short acting formulation; patients with exposures to both prefer the ease of the long acting formulation.^{110 116} One year follow-up

Table 2 | Treatment recommendations

Drugs	Recommended dosing	Common side effects	AAN guideline ^{96 97}	IMDA guidelines ⁹⁹	Notes
Propranolol, propranolol LA: non-selective β adrenergic receptor antagonist	Start 10 mg orally TID; up to 360 mg in divided doses; LA given once daily	Bradycardia, bronchospasm, hypotension, fatigue, lightheadedness, sexual dysfunction, depression	First line therapy	First line therapy	Other β blockers such as nadolol, sotalol, and arotinolol have second line recommendations; patients who do not respond to one β blocker will not respond to any
Primidone: metabolized to phenylethylmalonamide and phenobarbital; effect is independent of its phenobarbital metabolite ^{100 101}	Start 25 mg orally nightly; can titrate into divided doses up to 750 mg daily	Dizziness, fatigue, malaise	First line therapy	First line therapy	Side effects often dissipate early
Topiramate: stimulation of GABA activity; inhibition of carbonic anhydrase; antagonizes AMPA/kainite receptors; blockade of voltage dependent calcium and sodium channels	Start 25 mg BID; can increase up to 150-400 mg/day	Paresthesias, impaired attention, decreased appetite, nausea, fatigue, memory difficulties	Second line therapy; "probably effective"	First line therapy	Side effect profile often cause for cessation
Gabapentin: interacts with auxiliary subunit of voltage sensitive calcium channels ¹⁰²	Start 100-300 mg TID; can titrate up to 3600 mg daily	Lethargy/drowsiness, fatigue, decreased libido, dizziness, increased anxiety, shortness of breath	Second line therapy; "probably effective" as monotherapy	Second line therapy	Higher dosing does not increase side effect profile
Alprazolam: positive allosteric modulators on GABA-A receptor	Start 0.25 mg daily or 0.125 mg daily in elderly; average dose 0.125-3 mg/day	Sedation, cognitive impairment	Second line therapy	Second line therapy	Potential for misuse
Clonazepam: positive allosteric modulators on GABA-A receptor	Start 0.5 mg daily; average dose 1.5-2.0 mg daily	Sedation, cognitive impairment	Second line therapy	Not recommended	Potential for misuse
Zonisamide: inhibits T type calcium channels; weak inhibitor of carbonic anhydrase	Start 100 mg daily; average dose 225 mg in divided doses	Headache, nausea, fatigue/sleepiness, diarrhea	Not recommended	Second line therapy	-
Olanzapine: DA receptor blocker	Start 5 mg daily; average dose 10-20 mg/day	Weight gain, somnolence, extrapyramidal symptoms	Not recommended	Second line therapy	-
Clozapine: DA receptor blocker	Start 25 mg once a day; 12.5 mg in elderly; average dose 25-75 mg/day	Sedation, QT prolongation, orthostatic hypotension	Third line therapy; "possibly effective"	Second line therapy	Must monitor for agranulocytosis
Nimodipine: calcium channel blocker	Start 30 mg once a day; average dose 120 mg/day	Hypotension, diarrhea, dyspepsia	Third line therapy; "possibly effective"	Not recommended	-
Chemodenervation					
Botulinum toxin	Depends on muscle location	Weakness, dysphagia (neck injections), breathing difficulties (neck injections)	Recommended in medically refractory cases	Recommended in medically refractory cases	-
Surgical interventions					
Thalamotomy	Thalamus-ViM	Weakness, numbness	Case based decision	Not recommended	Delayed effect; may have progressive extension of lesion
Deep brain stimulation	ViM (unilateral preferred > bilateral); Czl	Limb paresthesia (usually improves with programming adjustments), dysarthria, disequilibrium, skin infections/breakdown	ViM recommended in medically refractory cases; no recommendations for Czl	ViM recommended in medically refractory cases; no recommendations for Czl	Bilateral ViM increases risk of dysarthria and disequilibrium
MRI guided focused ultrasound ^{103 104}	ViM (unilateral)	Dizziness (early), nausea/vomiting (early), headache (early), flushing (early), ataxia (late), paresthesias (late)	Recommended in medically refractory cases	Recommended in medically refractory cases	Rare cases with significant ataxia requiring walkers

AAN=American Academy of Neurology; AMPA=α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; BID=twice daily; Czl=caudal zona incerta; DA=dopamine; GABA=γ amino butyric acid; IMDA=Italian Movement Disorders Association; LA=long acting; MRI=magnetic resonance imaging; TID=three times daily; ViM=ventral intermediate nucleus.

of patients taking propranolol showed a continued but sometimes reduced response to treatment; some patients needed dose increases.^{117 118}

Propranolol is contraindicated in patients with bronchial asthma and allergic rhinitis; selective β blockers might be considered in these cases. The AAN guidelines recommend the selective β blocker atenolol (100 mg daily) as “probably effective.”¹¹⁹

Propranolol should be used with caution in patients with diabetes mellitus, as the adrenergic signs and symptoms of hypoglycemia can be masked. In the absence of contraindications, patients with stable heart failure due to left ventricular systolic dysfunction may take propranolol.¹²⁰

Patients who do not respond to propranolol do not respond to other β receptor blocking drugs. If a patient cannot take propranolol for some reason but could take an alternate non-selective β receptor blocker, three other non-selective β blockers have indications for use as second line therapy. One multicenter crossover trial (n=145 completed study) reported that the response of tremor to arotinolol was significantly better than that to propranolol (30 mg daily arotinolol v 160 mg daily propranolol; P=0.002) on motor task assessment.¹²¹ A randomized, double blind, placebo controlled trial in 24 patients found that sotalol (80 mg twice daily) was significantly better than placebo for the treatment of essential tremor (P<0.01); its effects were not compared

directly with response to propranolol.¹²² Nadolol was compared with placebo in a 10 person double blind crossover trial and shown to have efficacy at 120 mg and 240 mg daily dosing. The higher dose had no additional benefit.¹²³

Anticonvulsants

Primidone is also a recommended first line treatment for essential tremor. Primidone is as effective as propranolol and may be more likely to completely suppress limb tremor.^{100 109 124} A double blind comparative study (n=113) showed that all doses of primidone improved limb tremor. Lower doses of 250 mg were as good as or better than higher doses of 750 mg.¹²⁵ Reduction of tremor does not necessarily translate to improved function. An observational study of 11 patients initially responsive to primidone reported loss of efficacy and discontinuation (n=3) of the drug. The reduction in magnitude of tremor was 45% (SD 41%) at four weeks on accelerometric evaluation, and it was 41% (34%) at 12 months in the patients remaining on the drug.¹²⁶ A retrospective chart review (n=30) reported that approximately 50% (n=14) of patients taking primidone had improvement in vocal tremor. Head tremor does not consistently respond to primidone.¹²⁷⁻¹²⁹

Topiramate is recommended as first line treatment for essential limb tremor by the IMDA and as a second line treatment by the AAN. In a large multicenter,

Table 3 | Sample of level 1 evidence (randomized controlled trials) for propranolol in limb tremor. Shows small size, short duration, variability in definition of essential tremor, and dropout/side effect profile for propranolol

Trial	Dropout	Definition of essential tremor	Dosing	Study length	Side effects of propranolol
Propranolol v placebo (n=33) ¹⁰⁵	n=3: 1 syncope; 2 related to “other disease”	Not defined	Up to 40 mg TID	4 months	1 patient at month 4 stopped due to AV block; 24 reports of SE (insomnia and headache most common)
Propranolol v metoprolol (n=16) ¹⁰⁶	None	Not defined	Propranolol 120 mg, 240 mg daily	10 weeks; 2 weeks on each arm (low dose week always before high dose)	2/16 could not be increased to higher doses owing to SE on lower dose
Propranolol v phenobarbital v placebo (n=17) ¹⁰⁷	n=5 (not detailed)	Not defined	Propranolol 1.7 (SD 0.10) mg/kg	1 month on each treatment	Propranolol: lower BP and pulse (number not provided)
Propranolol v metoprolol (n=23) ¹⁰⁸	n=33 dropped out due to asthma exacerbations	Postural tremor affecting upper extremities and neck	Propranolol 120 mg, 240 mg (divided dose)	11 weeks (2 weeks each arm and 1 week washout in between)	Both drugs: headache, dizziness; propranolol: dizziness, rash, impotence (numbers not given)
Propranolol v primidone v placebo (n=19) ¹⁰⁹	n=5: 1 propranolol “subtherapeutic”; 1 SE propranolol; 4 SE primidone	Not defined	Propranolol 40 mg TID	10 days on maximum dose of each drug	Propranolol SEs not addressed
Propranolol v propranolol LA (n=23) ¹¹⁰	n=8: 1 SE; 1 worse tremor; 6 personal reasons	Posture and action tremor in hands in absence of other neurologic signs	80 mg TID, 160 mg LA, 240 mg LA, 320 mg LA, (placebo)	15 weeks (3 weeks each arm)	80 mg: n=2; 160 mg LA: n=4; 240 mg LA: n=5; 320 mg LA: n=5
Propranolol v theophylline v placebo (n=10) ¹¹¹	None	Tremor absent at rest; tremor apparent in posture; tremor not exacerbated by movement; no signs of PD or cerebellar disease	80 mg propranolol	1 month on each treatment	Propranolol (n=3): anxiety, sleep disturbance, dizziness; theophylline: no SE
Propranolol v gabapentin v placebo (n=16) ¹¹²	None	Chronic persistent postural tremor with or without kinetic tremor	Propranolol 40 mg TID	13 day treatment, then 1 day of washout	Propranolol: 5 events (3 instability (1 disabling), 1 depressive symptoms, 1 abdominal cramping)
Propranolol v olanzapine (n=38) ¹¹³	None	Definition based on Tremor Research Group Criteria	Propranolol 120 mg/day	1 month on each drug	Propranolol: 27 events: fatigue, nausea, impotence most common

AV=atrioventricular; BP=blood pressure; LA=long acting; PD=Parkinson’s disease; SE=side effects; TID=three times daily.

double blind, placebo controlled, parallel design study (n=108 topiramate, 100 placebo) use of topiramate improved scores on the Fahn-Tolosa-Marin Tremor Rating Scale by approximately 30%. Improvements in function and disability were seen ($P<0.001$).¹³⁰ A meta-analysis of randomized controlled trials reported improvement in motor skills and functional disability as well.¹³¹ The side effect profile contributes to a high rate of drug cessation.^{130 132}

Gabapentin is a second line treatment in both guidelines. AAN recommendations were based on a comparative, double blind, placebo controlled trial in which 16 patients received 400 mg gabapentin three times daily in the treatment arm. After 15 days of treatment, a mild to moderate reduction of tremor was seen, which was not significantly different from that seen with propranolol 120 mg daily.¹¹² A double blind, placebo controlled, crossover trial reported modest improvements in limb tremor at 1800 mg and 2700 mg gabapentin daily in divided doses, with no significant difference in efficacy between the two doses in the 20/25 patients who completed the trial.¹⁰²

Benzodiazepines—Two benzodiazepines, alprazolam and clonazepam, are recommended as second line treatments. A double blind, placebo controlled parallel study (n=24) reported clinical improvement in patients taking alprazolam ($P<0.01$).¹³³ Rating scales and psychomotor tests were used for assessment, not accelerometry. Another double blind, placebo controlled trial (n=22) reported that the functional ability and global functioning subsets of a “tremor intensity” rating scale improved ($P=0.03$) in patients treated with alprazolam.¹³⁴ A double blind, placebo controlled trial of clonazepam showed benefit in patients (n=15) receiving up to 4 mg of clonazepam daily ($P<0.001$).¹³⁵ A later study of 14 patients with severe kinetic tremor reported a mean tremor reduction of 71% on accelerometry; the mean clonazepam dose was 2.2 mg.¹³⁶

Zonisamide—Weak evidence supports the use of zonisamide in essential tremor. A 2017 Cochrane review found insufficient evidence to support the efficacy and safety of its use.¹³⁷ However, the IMDA recognizes zonisamide as a second line treatment. A double blind, placebo controlled trial (n=20) reported improvement in tremor accelerometry.¹³⁸ An evaluator blinded open treatment trial (n=25) found that approximately a third of patients had at least moderate improvement.¹³⁹

Antipsychotics

Antipsychotics have some benefit in essential limb tremor. In an open label prospective trial, 37 patients received olanzapine, most taking 10-20 mg daily in divided doses.¹⁴⁰ Tremor significantly improved, and the effect was maintained over six months. Sedative side effects lessened one week after the start of treatment. A randomized, double blind, crossover study compared the efficacy of olanzapine (20 mg/day) and propranolol (120 mg/day) in a group of 38 patients who had previously not responded to at least one other drug for essential tremor.¹¹³

Both drugs significantly improved tremor, and no significant difference in the efficacy of the two drugs was seen after 30 days of treatment. Almost 40% of patients taking olanzapine reported that their tremor completely disappeared, and around 58% had a slight/barely noticeable tremor. Patients in this study did not have any significant side effects.

In an open label trial, 12 patients with essential tremor were in a group receiving clozapine, with doses ranging from 18 mg to 36 mg.¹⁴¹ Seven had a marked improvement in tremor, two had mild improvement, and three had no benefit. In a randomized, double blind, crossover study, 15 patients who had side effects or were resistant to propranolol or primidone were given 12.5 mg of clozapine.¹⁴² Those who had a greater than 50% tremor response were asked to stay in an open label arm of the trial and allow examiners to follow their response. Patients were treated with up to 50 mg/day and were followed for between one and two years. Thirteen patients agreed to enter this arm, and all patients continued to have clinical response throughout the study. No signs of tolerance were seen, and most patients with sedation found that this significantly diminished after a six to seven week period.

Other drugs

AAN guidelines state that nimodipine may be effective in treating essential tremor. In a small double blind, placebo controlled trial, nimodipine was dosed at 30 mg four times daily to 16 patients with essential tremor. Of the 15 patients who completed the trial, tremor improved in eight after they had been taking the drug for two weeks.

Chemodenervation

The IMDA and the 2005 AAN practice parameters recommend botulinum toxin injections in medically refractory cases of essential tremor. In 1996 the first randomized, double blind, placebo controlled trial (n=25, 13 in treatment arm) reported modest outcomes in patients with essential tremor treated with onabotulinum toxin.¹⁴³ Patients in the treatment arm received 50 units of toxin (15 units flexor carpi radialis, 15 units flexor carpi ulnaris, 10 units extensor carpi radialis, 10 units extensor carpi ulnaris). Another set of injections was administered four weeks later in doubled doses in the case of no clinical response and no weakness. Patients reported modest improvements, but no significant improvement in function was seen.

In 2001 a randomized controlled trial compared the effect of low versus high doses of onabotulinum toxin on limb tremor in essential tremor. Patients were randomized to one of three interventions targeting the same muscles as the previous trial: injections totaling 50 units, 100 units, or placebo.¹⁴⁴ Patients reported subjective improvement with low dose and high dose toxin injections (75% treatment v 27% placebo; $P<0.05$). The postural component of the tremor showed sustained benefit over the course of treatment in both treatment arms. However, kinetic tremor improved significantly only six weeks

after injection. Approximately 30% of the patients in the low dose group and 70% of those in the high dose group experienced weakness.

Criticism of these initial studies included the uniform selection of muscles for injection despite the variability in muscle involvement and directionality of essential limb tremor. Additionally, the complexity and variability of essential limb tremor is challenging, with clinicians' visual assessment in agreement with kinematic assessment only 36% of the time.¹⁴⁵ To improve outcomes, later studies sought methods to individualize injections. An open label study of 20 patients studied the effects of abobotulinum toxin injections up to six months after a single treatment.¹⁴⁶ Injectors identified the involved muscles through use of accelerometry and electromyography. When possible, extensor carpi muscles were avoided owing to an increased risk of weakness of finger extension in the third digit. Electromyography guidance was not used. Significant improvement on the Activities of Daily Living Self-Questionnaire was seen at one month (33.1 (SD 14.83) v 19.1 (9.55); $P < 0.05$) and three months (33.1 (17.70); $P < 0.001$) after injections.

The open label study of patients receiving botulinum toxin A with the longest reported follow-up followed 10 patients receiving incobotulinum toxin injections every four months.¹⁴⁷ Dosing patterns were determined through kinematic tremor assessment using motion sensors. In this manner, injections were tailored to the muscles associated with a patient's tremor (wrist flexion/extension, pronation/supination, proximal arm flexion/extension) rather than using a predetermined dosing at a predetermined location. Patients had a significant improvement in function and tremor over the 96 weeks of the study. The main side effect, weakness, improved with dose reduction.

A randomized, double blind, placebo controlled, crossover trial published in 2018 reported benefit of customizing injections of incobotulinum toxin with electromyography guidance for patients with essential tremor.¹⁴⁸ Statistically significant improvement in tremor severity as measured on the Fahn-Tolosa-Marin Tremor Score was reported at four weeks (2 v 3; $P = 0.003$) and eight weeks (2 v 3; $P < 0.001$) Minimal hand weakness (~4%) was reported. The success of treatment was attributed to avoidance of the extensor muscles, the use of low dose injections into flexor muscles (often 10 units), and customization of the injections. Patients rarely received more than 100 units of toxin. Benefits were seen at four and eight week assessments after injections.

One double blind, placebo controlled trial has looked at botulinum toxin for neck tremor.¹⁴⁹ Three of the 10 patients in the trial did not have hand tremor and would not meet criteria for the current definition of essential tremor. Half of the study patients had a moderate to marked response to injections: bilateral sternocleidomastoid muscles (40 U/muscle) and splenius capitus muscles (60 U/muscle).

Open label trials have shown benefit of botulinum toxin injections for voice tremor in essential tremor.¹⁵⁰⁻¹⁵¹ The main side effect was local muscle weakness causing impaired phonation and breathy voice. A retrospective study of patients with vocal tremor in essential tremor provides guidelines for muscle selection and reports a consistent clinical response with repeated injections.¹⁵² Notably, many of these patients would now be "essential tremor plus," as half of the study patients had comorbid dystonia. A randomized, prospective, crossover study comparing botulinum toxin with injection augmentation of the vocal cords ($n = 7$) found no advantage with augmentation.¹⁵³

Surgical interventions

Deep brain stimulation

Before the 1990s, the main surgical intervention for essential tremor was thalamic lesioning. However, this approach fell out of favor with the development of deep brain stimulation (DBS). DBS can be done with or without general anesthesia. A frontal burr hole is drilled and then electrodes are implanted. Microelectrode and macroelectrode recordings can be used to assist in location of leads. The intracranial electrodes are ultimately connected to an implanted pulse generator.

Although alternative lead locations are under assessment, the approach for most surgeries in essential tremor is to target unilateral or bilateral lead placement in the thalamic ventral intermediate nucleus (ViM).¹⁵⁴⁻¹⁵⁶ Improvement of tremor is thought to be due to the disruption of the synchronous firing in the ViM. Patients undergoing DBS in the ViM report improvement in severity of limb tremor and activities of daily living, as well as non-motor symptoms such as "tense feelings."¹⁵⁷⁻¹⁵⁸ A retrospective analysis of a patient cohort who had ViM DBS, including 28 patients with essential tremor, found sustained reduction in limb tremor 10 years after surgery, although some loss in efficacy was seen over time—66% improvement from baseline in year one and 48% improvement from baseline in year 10.¹⁵⁹ Head tremor often improves with both unilateral and bilateral ViM placement. Studies have shown inconsistent improvement in voice tremor.¹⁶⁰⁻¹⁶² Common side effects are listed in table 2.

Implantation in the caudal zona incerta (cZI) is an alternative to ViM lead placement. A retrospective study comparing ViM ($n = 17$) with cZI targeting ($n = 19$) suggested that cZI was a superior target.¹⁶³ A study of 15 consecutively recruited patients with essential tremor who had bilateral cZI DBS showed significant improvements in action tremor, proximal tremor, and activities of daily living. Benefits were sustained for up to seven years.¹⁶⁴

Focused ultrasound

MRI guided high intensity focused ultrasound (MRIGFUS) is a lesional surgery that is less invasive than DBS. The current procedure allows penetration

of the skull without heating of the bone. The thalamic ViM nucleus is the typical lesion location.

In an open label uncontrolled pilot study, 15 patients with severe, drug refractory essential tremor underwent MRIgFUS lesioning of the ViM nucleus.¹⁶⁵ Significant improvements were seen in tremor, disability, and quality of life scores. Two additional open label trials in the following year reported sustained improvement of tremor (three to six months) with minimal side effects.^{166 167}

Subsequently, a double blind trial (n=76) randomized medically refractory essential tremor patients to unilateral ablation versus sham surgery in a three to one ratio. Assessments were done one, three, six, and 12 months after surgery, using the Clinical Rating Scale for Tremor to measure tremor severity.¹⁶⁸ Three months after surgery, a 47% improvement of hand tremor was seen in the interventional arm compared with 0.1% in the sham procedure group. The between group difference was 8.3 (95% confidence interval 5.9 to 10.7) points. Continued benefit was seen at 12 months, with 40% improvement from baseline in tremor on the treated side, a difference of 7.2 (6.1 to 8.3; P<0.001) points from baseline. No significant improvement in tremor was seen on the untreated side. The study also found sustained improvement in quality of life and functional ability scores. Objective ataxia (20% of patients) and subjective balance difficulties (16% of patients) were reported after surgery and persisted in a few patients (4-5%).

As of the date of this literature search, the longest reported duration of follow-up for MRIgFUS was two years. A study of 37 patients with FUS surgery between 2012 and 2016 at two clinical sites reported persistent benefits on tremor, with 75% of patients having at least partial tremor reduction.¹⁶⁹ In this trial, sustained benefit was seen at two years, but with diminishing efficacy. Almost 46% of patients had significant reduction in tremor at year one; at year two, a 35% reduction was seen. The authors hypothesized that the causes of the diminishing effect may be multifactorial, including diminishing lesion size, reduction in perilesional edema, or inaccurate targeting. A prospective, multicenter, randomized trial also reported sustained benefit at two year follow-up, with 62% of patients showing a 50% improvement in tremor rating. Two patients were tremor-free. Mild progression of tremor and disability scores was seen between years one and two.¹⁷⁰ Adverse reactions are summarized in table 2.

As technology advances, the technique used for MRIgFUS improves. A retrospective cohort study used diffusion weighted MRI with tractography in 66 patients to assess the lesion location that provided the best clinical outcome in patients undergoing ViM lesioning with FUS.¹⁷¹ The area straddling the border of the ViM and the ventro-caudalis nucleus was identified. This area was distinct from areas that caused side effects. Lesions larger than 170 mm³ significantly increased the risk of side effects.

Small prospective trials have shown benefit in using tractography to identify the location to lesion and shown the viability of using 1.5 T MRI for the procedure.¹⁷²⁻¹⁷⁴

Lifestyle management

Patients with essential tremor may have considerable challenges in writing, eating, and using household devices. Use of weighted devices (pens, computer mouse) can help to reduce the amplitude of tremor. Devices are available to help patients to button clothes, write, drink, and eat. A non-invasive handheld device, designed to stabilize tremor when eating, was shown to be beneficial in 11/15 patients in a small pilot study.¹⁷⁵

Emerging therapies

New approaches to treatment are under investigation. As many patients report alcohol responsive tremors, one novel drug being explored is 1-octanol, a long chain alcohol. A phase I/II double blind, placebo controlled trial tested 4 mg/kg daily doses (rounded to the nearest 50 mg) of 1-octanol in 19 patients with essential tremor and reported significant improvement of tremor at 300 minutes (dominant hand, $F_{1,16}=5.49$, P=0.032 v placebo), with a trend to improvement 150 minutes after treatment.¹⁷⁶ Doses up to at least 128 mg can be tolerated.¹⁷⁷

Perampanel, a selective, non-competitive α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist that blocks glutamate activity in postsynaptic AMPA receptors, is another drug of interest. In a pilot study, all eight patients ultimately taking 4 mg of perampanel at night had improved tremor 56 days later and half of the patients had greater than 50% improvement on the Tremor Clinical Rating Scale (52.13 (SD 5.84) at baseline to 26.1 (9.46); P<0.001).¹⁷⁸ Results from a double blind, crossover, placebo controlled trial on the efficacy and tolerability of perampanel are pending.

Non-invasive neuromodulation through ulnar and radial nerve stimulation is a novel approach to treatment of essential tremor that is under investigation. A sham controlled pilot study (n=23) showed up to 60% reduction in tremor in the patients with the device (rating scores: stimulation 1.77 (SD 0.21) v sham 2.77 (0.22); P=0.01) Transient redness and pruritus were the most common side effects reported.¹⁷⁹ Transcranial magnetic stimulation is also being explored as a treatment option.

Guidelines

At the time of this review, the AAN and the IMDA had produced guidelines for the management of essential tremor.⁹⁶⁻⁹⁸ The Quality Standards Subcommittee of the AAN initially published guidelines in 2005 and updated them in 2011. The IMDA guidelines were published in 2013. Whereas the AAN guidelines make no specific dosing recommendations, the Italian guidelines do. Both guidelines endorse propranolol

RESEARCH QUESTIONS

1. Can we improve phenotyping of essential tremor to achieve gene identification and improved treatment response?
2. How should we interpret the presence of dystonia in patients with essential tremor?
3. What are the long term responses to current interventions for essential tremor?

and primidone as first line treatment, and both recommend gabapentin and alprazolam as second line treatment. They make no recommendations for polytherapy. In medically refractory cases, botulinum toxin injections, ViM deep brain stimulation, and guided focused ultrasound of the ViM are endorsed in both guidelines. However, some discrepancies exist, and these are highlighted in table 2.

Conclusion

In the past decade, the variability of the symptoms, disease course, and response to treatment of essential tremor has led to the recognition of essential tremor as a syndrome. A new classification system has made a first attempt to characterize essential tremor better. Challenges remain with this new classification, as “soft” signs are not clearly defined and confusion remains as to whether all “soft” signs should really be placed into an “essential tremor plus” category, and further revisions to this classification system will likely be needed. Although surgical approaches to the treatment of essential tremor have expanded, no oral drug has emerged that surpasses the efficacy of the first line treatments (propranolol and primidone) identified decades ago.

Contributors: VS wrote the review. A medical librarian, Rachel Pinotti, assisted in the literature search.

Competing interests: I have read and understood the BMJ policy on declaration of interests and declare the following interests: none.

Provenance and peer review: Commissioned; externally peer reviewed.

Patient involvement: Patients reviewed the manuscript and the videos.

Patient consent: The patients in the video have provided written consent.

- 1 Bhatia KP, Bain P, Bajaj N, et al. Tremor Task Force of the International Parkinson and Movement Disorder Society. Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. *Mov Disord* 2018;33:75-87. doi:10.1002/mds.27121
- 2 Louis ED, Rios E, Henchcliffe C. How are we doing with the treatment of essential tremor (ET)? Persistence of patients with ET on medication: data from 528 patients in three settings. *Eur J Neurol* 2010;17:882-4. doi:10.1111/j.1468-1331.2009.02926.x
- 3 Louis ED, Marder K, Cote L, et al. Differences in the prevalence of essential tremor among elderly African Americans, whites, and Hispanics in northern Manhattan, NY. *Arch Neurol* 1995;52:1201-5. doi:10.1001/archneur.1995.00540360079019
- 4 Louis ED. The Roles of Age and Aging in Essential Tremor: An Epidemiological Perspective. *Neuroepidemiology* 2019;52:111-8. doi:10.1159/000492831
- 5 Louis ED, Broussolle E, Goetz CG, Krack P, Kaufmann P, Mazzoni P. Historical underpinnings of the term essential tremor in the late 19th century. *Neurology* 2008;71:856-9. doi:10.1212/01.wnl.0000325564.38165.d1
- 6 Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. *Mov Disord* 2010;25:534-41. doi:10.1002/mds.22838
- 7 Louis ED, Dogu O. Does age of onset in essential tremor have a bimodal distribution? Data from a tertiary referral setting and a population-based study. *Neuroepidemiology* 2007;29:208-12. doi:10.1159/000111584
- 8 Hopfner F, Ahlf A, Lorenz D, et al. Early- and late-onset essential tremor patients represent clinically distinct subgroups. *Mov Disord* 2016;31:1560-6. doi:10.1002/mds.26708
- 9 Ghosh D, Brar H, Lhamu U, Rothner AD, Erenberg G. A Series of 211 Children with Probable Essential Tremor. *Mov Disord Clin Pract* 2016;4:231-6. doi:10.1002/mdc3.12385
- 10 Brennan KC, Jurewicz EC, Ford B, Pullman SL, Louis ED. Is essential tremor predominantly a kinetic or a postural tremor? A clinical and electrophysiological study. *Mov Disord* 2002;17:313-6. doi:10.1002/mds.10003
- 11 Louis ED. The primary type of tremor in essential tremor is kinetic rather than postural: cross-sectional observation of tremor phenomenology in 369 cases. *Eur J Neurol* 2013;20:725-7. doi:10.1111/j.1468-1331.2012.03855.x
- 12 Louis ED, Wendt KJ, Pullman SL, Ford B. Is essential tremor symmetric? Observational data from a community-based study of essential tremor. *Arch Neurol* 1998;55:1553-9. doi:10.1001/archneur.55.12.1553
- 13 Deuschl G, Krack P, Lauk M, Timmer J. Clinical neurophysiology of tremor. *J Clin Neurophysiol* 1996;13:110-21. doi:10.1097/00004691-199603000-00002
- 14 Louis ED, Hernandez N, Michalec M. Prevalence and correlates of rest tremor in essential tremor: cross-sectional survey of 831 patients across four distinct cohorts. *Eur J Neurol* 2015;22:927-32. doi:10.1111/ene.12683
- 15 Louis ED, Asabere N, Agnew A, et al. Rest tremor in advanced essential tremor: a post-mortem study of nine cases. *J Neurol Neurosurg Psychiatry* 2011;82:261-5. doi:10.1136/jnnp.2010.215681
- 16 Louis ED, Frucht SJ, Rios E. Intention tremor in essential tremor: Prevalence and association with disease duration. *Mov Disord* 2009;24:626-7. doi:10.1002/mds.22370
- 17 Deuschl G, Wenzelburger R, Löffler K, Raethjen J, Stolze H. Essential tremor and cerebellar dysfunction clinical and kinematic analysis of intention tremor. *Brain* 2000;123:1568-80. doi:10.1093/brain/123.8.1568
- 18 Kestenbaum M, Michalec M, Yu Q, Pullman SL, Louis ED. Intention Tremor of the Legs in Essential Tremor: Prevalence and Clinical Correlates. *Mov Disord Clin Pract* 2015;2:24-8. doi:10.1002/mdc3.12099
- 19 Poston KL, Rios E, Louis ED. Action tremor of the legs in essential tremor: prevalence, clinical correlates, and comparison with age-matched controls. *Parkinsonism Relat Disord* 2009;15:602-5. doi:10.1016/j.parkreldis.2008.11.006
- 20 Martinez-Hernandez HR, Louis ED. Macrographia in essential tremor: a study of patients with and without rest tremor. *Mov Disord* 2014;29:960-1. doi:10.1002/mds.25894
- 21 Louis ED, Michalec M, Gillman A. Shaky drawing: what is the rate of decline during prospective follow-up of essential tremor? *BMJ Open* 2014;4:e004626. doi:10.1136/bmjopen-2013-004626
- 22 Louis ED, Agnew A, Gillman A, Gerbin M, Viner AS. Estimating annual rate of decline: prospective, longitudinal data on arm tremor severity in two groups of essential tremor cases. *J Neurol Neurosurg Psychiatry* 2011;82:761-5. doi:10.1136/jnnp.2010.229740
- 23 Louis ED, Gerbin M, Mullaney MM. What is the functional significance of nondominant arm tremor in essential tremor? *Mov Disord* 2010;25:2674-8. doi:10.1002/mds.23284
- 24 Louis ED, Dogu O. Isolated head tremor: part of the clinical spectrum of essential tremor? Data from population-based and clinic-based case samples. *Mov Disord* 2009;24:2281-5. doi:10.1002/mds.22777
- 25 Schrag A, Münchau A, Bhatia KP, Quinn NP, Marsden CD. Essential tremor: an overdiagnosed condition? *J Neurol* 2000;247:955-9. doi:10.1007/s004150070053
- 26 Louis ED. When do essential tremor patients develop head tremor? Influences of age and duration and evidence of a biological clock. *Neuroepidemiology* 2013;41:110-5. doi:10.1159/000351698
- 27 Hardesty DE, Maraganore DM, Matsumoto JY, Louis ED. Increased risk of head tremor in women with essential tremor: longitudinal data from the Rochester Epidemiology Project. *Mov Disord* 2004;19:529-33. doi:10.1002/mds.20096
- 28 Wright BA, Michalec M, Louis ED. Triggering essential head tremor with sustained phonation: a clinical phenomenon with potential diagnostic value. *Parkinsonism Relat Disord* 2014;20:230-2. doi:10.1016/j.parkreldis.2013.10.019
- 29 Agnew A, Frucht SJ, Louis ED. Supine head tremor: a clinical comparison of essential tremor and spasmodic torticollis patients. *J Neurol Neurosurg Psychiatry* 2012;83:179-81. doi:10.1136/jnnp-2011-300823

- 30 Leegwater-Kim J, Louis ED, Pullman SL, et al. Intention tremor of the head in patients with essential tremor. *Mov Disord* 2006;21:2001-5. doi:10.1002/mds.21079
- 31 Eken HN, Louis ED. Agnosia for head tremor in essential tremor: prevalence and clinical correlates. *J Clin Mov Disord* 2016;3:4. doi:10.1186/s40734-016-0032-0
- 32 Robakis D, Louis ED. Head tremor in essential tremor: "Yes-yes", "no-no", or "round and round"? *Parkinsonism Relat Disord* 2016;22:98-101. doi:10.1016/j.parkreldis.2015.11.002
- 33 Michalec M, Gillman A, Louis ED. Incidence rates of cranial tremors in essential tremor: a prospective, longitudinal study. *Neuroepidemiology* 2014;43:150-4. doi:10.1159/000368334
- 34 Louis ED, Rios E, Applegate LM, Hernandez NC, Andrews HF. Jaw tremor: prevalence and clinical correlates in three essential tremor case samples. *Mov Disord* 2006;21:1872-8. doi:10.1002/mds.21069
- 35 Sulica L, Louis ED. Clinical characteristics of essential voice tremor: a study of 34 cases. *Laryngoscope* 2010;120:516-28. doi:10.1002/lary.20702
- 36 Moraes BT, Biase NG. Laryngoscopy evaluation protocol for the differentiation of essential and dystonic voice tremor. *Braz J Otorhinolaryngol* 2016;82:88-96. doi:10.1016/j.bjorl.2015.11.001
- 37 Elble R, Bain P, Forjaz MJ, et al. Task force report: scales for screening and evaluating tremor: critique and recommendations. *Mov Disord* 2013;28:1793-800. doi:10.1002/mds.25648
- 38 Louis ED, Gerbin M, Galecki M. Essential tremor 10, 20, 30, 40: clinical snapshots of the disease by decade of duration. *Eur J Neurol* 2013;20:949-54. doi:10.1111/ene.12123
- 39 Putzke JD, Whaley NR, Baba Y, Wszolek ZK, Uitti RJ. Essential tremor: predictors of disease progression in a clinical cohort. *J Neurol Neurosurg Psychiatry* 2006;77:1235-7. doi:10.1136/jnnp.2005.086579
- 40 Hopfner F, Erhart T, Knudsen K, et al. Testing for alcohol sensitivity of tremor amplitude in a large cohort with essential tremor. *Parkinsonism Relat Disord* 2015;21:848-51. doi:10.1016/j.parkreldis.2015.05.005
- 41 Junker J, Brandt V, Berman BD, et al. Predictors of alcohol responsiveness in dystonia. *Neurology* 2018;91:e2020-6. doi:10.1212/WNL.0000000000006551
- 42 Koller WC. Alcoholism in essential tremor. *Neurology* 1983;33:1074-6. doi:10.1212/WNL.33.8.1074
- 43 Rautakorpi I, Marttila RJ, Rinne UK. Alcohol consumption of patients with essential tremor. *Acta Neurol Scand* 1983;68:177-9. doi:10.1111/j.1600-0404.1983.tb05345.x
- 44 Louis ED, Jurewicz EC, Applegate L, Luchsinger JA, Factor-Litvak P, Parides M. Semiquantitative study of current coffee, caffeine, and ethanol intake in essential tremor cases and controls. *Mov Disord* 2004;19:499-504. doi:10.1002/mds.20035
- 45 Knudsen K, Lorenz D, Deuschl G. A clinical test for the alcohol sensitivity of essential tremor. *Mov Disord* 2011;26:2291-5. doi:10.1002/mds.23846
- 46 Singer C, Sanchez-Ramos J, Weiner WJ. Gait abnormality in essential tremor. *Mov Disord* 1994;9:193-6. doi:10.1002/mds.870090212
- 47 Cinar N, Sahin S, Okluoglu Onay T, Karsidag S. Balance in essential tremor during tandem gait: is the first mis-step an important finding? *Clin Neurosci* 2013;20:1433-7. doi:10.1016/j.jocn.2013.01.013
- 48 Prasad S, Velayutham SG, Reddam VR, Stezin A, Jhunjhunwala K, Pal PK. Shaky and unsteady: Dynamic posturography in essential tremor. *J Neurol Sci* 2018;385:12-6. doi:10.1016/j.jns.2017.12.003
- 49 Benito-León J, Louis ED, Bermejo-Pareja F. Neurological Disorders in Central Spain (NEDICES) Study Group. Reported hearing impairment in essential tremor: a population-based case-control study. *Neuroepidemiology* 2007;29:213-7. doi:10.1159/000112463
- 50 Ondo WG, Sutton L, Dat Vuong K, Lai D, Jankovic J. Hearing impairment in essential tremor. *Neurology* 2003;61:1093-7. doi:10.1212/01.WNL.0000086376.40750.AF
- 51 Balaban H, Altuntaş EE, Uysal IO, Sentürk IA, Topaktaş S. Audio-vestibular evaluation in patients with essential tremor. *Eur Arch Otorhinolaryngol* 2012;269:1577-81. doi:10.1007/s00405-011-1801-x
- 52 Applegate LM, Louis ED. Essential tremor: mild olfactory dysfunction in a cerebellar disorder. *Parkinsonism Relat Disord* 2005;11:399-402. doi:10.1016/j.parkreldis.2005.03.003
- 53 Quagliato LB, Viana MA, Quagliato EM, Simis S. Olfaction and essential tremor. *Arq Neuropsiquiatr* 2009;67:21-4. doi:10.1590/S0004-282X2009000100006
- 54 Louis ED, Jurewicz EC. Olfaction in essential tremor patients with and without isolated rest tremor. *Mov Disord* 2003;18:1387-9. doi:10.1002/mds.10603
- 55 Shah M, Muhammed N, Findley LJ, Hawkes CH. Olfactory tests in the diagnosis of essential tremor. *Parkinsonism Relat Disord* 2008;14:563-8. doi:10.1016/j.parkreldis.2007.12.006
- 56 Gitchei GT, Wetzel PA, Baron MS. Slowed saccades and increased square wave jerks in essential tremor. *Tremor Other Hyperkinet Mov (N Y)* 2013;3:tre-03-178-4116-2.
- 57 Wójcik-Pędziwiatr M, Plinta K, Krzak-Kubica A, et al. Eye movement abnormalities in essential tremor. *J Hum Kinet* 2016;52:53-64. doi:10.1515/hukin-2015-0193
- 58 Thenganatt MA, Louis ED. Personality profile in essential tremor: a case-control study. *Parkinsonism Relat Disord* 2012;18:1042-4. doi:10.1016/j.parkreldis.2012.05.015
- 59 Louis ED, Rios E. Embarrassment in essential tremor: prevalence, clinical correlates and therapeutic implications. *Parkinsonism Relat Disord* 2009;15:535-8. doi:10.1016/j.parkreldis.2008.10.006
- 60 Miller KM, Okun MS, Fernandez HF, Jacobson CE4th, Rodriguez RL, Bowers D. Depression symptoms in movement disorders: comparing Parkinson's disease, dystonia, and essential tremor. *Mov Disord* 2007;22:666-72. doi:10.1002/mds.21376
- 61 Puertas-Martín V, Villarejo-Galende A, Fernández-Guinea S, Romero JP, Louis ED, Benito-León J. A Comparison Study of Cognitive and Neuropsychiatric Features of Essential Tremor and Parkinson's Disease. *Tremor Other Hyperkinet Mov (N Y)* 2016;6:431.
- 62 Smeltzer L, Kuzņecovs V, Ertz R. Depression and social phobia in essential tremor and Parkinson's disease. *Brain Behav* 2017;7:e00781. doi:10.1002/brb3.781
- 63 Sengul Y, Sengul HS, Yucekaya SK, et al. Cognitive functions, fatigue, depression, anxiety, and sleep disturbances: assessment of nonmotor features in young patients with essential tremor. *Acta Neurol Belg* 2015;115:281-7. doi:10.1007/s13760-014-0396-6
- 64 Cochrane GD, Rizvi S, Abrantes A, Crabtree B, Cahill J, Friedman JH. Internal tremor in Parkinson's disease, multiple sclerosis, and essential tremor. *Parkinsonism Relat Disord* 2015;21:1145-7. doi:10.1016/j.parkreldis.2015.07.014
- 65 Chandran V, Pal PK, Reddy JY, Thennarasu K, Yadav R, Shivashankar N. Non-motor features in essential tremor. *Acta Neurol Scand* 2012;125:332-7. doi:10.1111/j.1600-0404.2011.01573.x
- 66 Azar M, Bertrand E, Louis ED, et al. Awareness of cognitive impairment in individuals with essential tremor. *J Neurol Sci* 2017;377:155-60. doi:10.1016/j.jns.2017.04.009
- 67 Bermejo-Pareja F, Puertas-Martín V. Cognitive features of essential tremor: a review of the clinical aspects and possible mechanistic underpinnings. *Tremor Other Hyperkinet Mov (N Y)* 2012;2:02-74-541-1.
- 68 Collins K, Rohl B, Morgan S, Huey ED, Louis ED, Cosentino S. Mild Cognitive Impairment Subtypes in a Cohort of Elderly Essential Tremor Cases. *J Int Neuropsychol Soc* 2017;23:390-9. doi:10.1017/S1355617717000170
- 69 Cersonsky TEK, Morgan S, Kellner S, et al. Evaluating Mild Cognitive Impairment in Essential Tremor: How Many and Which Neuropsychological Tests? *J Int Neuropsychol Soc* 2018;24:1084-98. doi:10.1017/S1355617718000747
- 70 Koller WC, Busenbark K, Miner K, Essential Tremor Study Group. The relationship of essential tremor to other movement disorders: report on 678 patients. *Ann Neurol* 1994;35:717-23. doi:10.1002/ana.410350613
- 71 Tan EK, Lee SS, S FC, Lum SY. Evidence of increased odds of essential tremor in Parkinson's disease. *Mov Disord* 2008;23:993-7. doi:10.1002/mds.22005
- 72 Fekete R, Jankovic J. Revisiting the relationship between essential tremor and Parkinson's disease. *Mov Disord* 2011;26:391-8. doi:10.1002/mds.23512
- 73 Tallón-Barranco A, Vázquez A, Javier Jiménez-Jiménez F, et al. Clinical features of essential tremor seen in neurology practice: a study of 357 patients. *Parkinsonism Relat Disord* 1997;3:187-90. doi:10.1016/S1353-8020(97)00031-X
- 74 Louis ED, Ottman R. Study of possible factors associated with age of onset in essential tremor. *Mov Disord* 2006;21:1980-6. doi:10.1002/mds.21102
- 75 Louis ED, Ford B, Wendt KJ, Lee H, Andrews H. A comparison of different bedside tests for essential tremor. *Mov Disord* 1999;14:462-7. doi:10.1002/1531-8257(199905)14:3<462::AID-MDS1012>3.0.CO;2-V
- 76 Sternberg EJ, Alcalay RN, Levy OA, Louis ED. Postural and Intention Tremors: A Detailed Clinical Study of Essential Tremor vs. Parkinson's Disease. *Front Neurol* 2013;4:51. doi:10.3389/fneur.2013.00051
- 77 Michalec M, Hernandez N, Clark LN, Louis ED. The spiral axis as a clinical tool to distinguish essential tremor from dystonia cases. *Parkinsonism Relat Disord* 2014;20:541-4. doi:10.1016/j.parkreldis.2014.01.021
- 78 Sternberg EJ, Alcalay RN, Levy OA, Louis ED. The "head snap": a subtle clinical feature during the finger-nose-finger maneuver in essential tremor. *Tremor Other Hyperkinet Mov (N Y)* 2013;3:tre-03-159-3719-1.
- 79 Louis ED. Twelve clinical pearls to help distinguish essential tremor from other tremors. *Expert Rev Neurother* 2014;14:1057-65. doi:10.1586/14737175.2014.936389
- 80 Sanes JN, Hallett M. Limb positioning and magnitude of essential tremor and other pathological tremors. *Mov Disord* 1990;5:304-9. doi:10.1002/mds.870050408

- 81 Phukan J, Albanese A, Gasser T, Warner T. Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. *Lancet Neurol* 2011;10:1074-85. doi:10.1016/S1474-4422(11)70232-0
- 82 Alty J, Cosgrove J, Thorpe D, Kempster P. How to use pen and paper tasks to aid tremor diagnosis in the clinic. *Pract Neurol* 2017;17:456-63. doi:10.1136/practneurol-2017-001719
- 83 Smits EJ, Tolonen AJ, Cluitmans L, et al. Standardized handwriting to assess bradykinesia, micrographia and tremor in Parkinson's disease. *PLoS One* 2014;9:e97614. doi:10.1371/journal.pone.0097614
- 84 Bajaj NP, Wang L, Gontu V, Grosset DG, Bain PG. Accuracy of subjective and objective handwriting assessment for differentiating Parkinson's disease from tremulous subjects without evidence of dopaminergic deficits (SWEDDS): an FP-CIT-validated study. *J Neurol* 2012;259:2335-40. doi:10.1007/s00415-012-6495-5
- 85 Kulkarni O, Lafaver K, Tarsy D. The "floating door sign" in Parkinson's disease. *Parkinsonism Relat Disord* 2013;19:825-6. doi:10.1016/j.parkreldis.2013.04.013
- 86 Rosenblum S, Samuel M, Zlotnik S, Erikh I, Schlesinger I. Handwriting as an objective tool for Parkinson's disease diagnosis. *J Neurol* 2013;260:2357-61. doi:10.1007/s00415-013-6996-x
- 87 Baur B, Schenk T, F urholzer W, et al. Modified pen grip in the treatment of Writer's Cramp. *Hum Mov Sci* 2006;25:464-73. doi:10.1016/j.humov.2006.05.007
- 88 Merati AL, Heman-Ackah YD, Abaza M, Altman KW, Sulica L, Belamowicz S. Common movement disorders affecting the larynx: a report from the neurology committee of the AAO-HNS. *Otolaryngol Head Neck Surg* 2005;133:654-65. doi:10.1016/j.otohns.2005.05.003
- 89 Comella C, Bhatia K. An international survey of patients with cervical dystonia. *J Neurol* 2015;262:837-48. doi:10.1007/s00415-014-7586-2
- 90 Molparia B, Schrader BN, Cohen E, et al. Combined accelerometer and genetic analysis to differentiate essential tremor from Parkinson's disease. *PeerJ* 2018;6:e5308. doi:10.7717/peerj.5308
- 91 Barrantes S, S anchez Egea AJ, Gonz alez Rojas HA, et al. Differential diagnosis between Parkinson's disease and essential tremor using the smartphone's accelerometer. *PLoS One* 2017;12:e0183843. doi:10.1371/journal.pone.0183843
- 92 Lin PC, Chen KH, Yang BS, Chen YJ. A digital assessment system for evaluating kinetic tremor in essential tremor and Parkinson's disease. *BMC Neurol* 2018;18:25. doi:10.1186/s12883-018-1027-2
- 93 Espay AJ, Lang AE, Erro R, et al. Essential pitfalls in "essential" tremor. *Mov Disord* 2017;32:325-31. doi:10.1002/mds.26919
- 94 Louis ED. Essential tremor: "Plus" or "Minus". Perhaps now is the time to adopt the term "the essential tremors". *Parkinsonism Relat Disord* 2018;56:111-2. doi:10.1016/j.parkreldis.2018.06.026
- 95 Rajalingam R, Breen DP, Lang AE, Fasano A. Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. *Parkinsonism Relat Disord* 2018;56:109-10. doi:10.1016/j.parkreldis.2018.06.029
- 96 Zesiewicz TA, Elble R, Louis ED, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2005;64:2008-20. doi:10.1212/01.WNL.0000163769.28552.CD
- 97 Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2011;77:1752-5. doi:10.1212/WNL.0b013e318236f0fd
- 98 Zappia M, Albanese A, Bruno E, et al. Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. *J Neurol* 2013;260:714-40. doi:10.1007/s00415-012-6628-x
- 99 Zappia M, Albanese A, Bruno E, et al. Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. *J Neurol* 2013;260:714-40. doi:10.1007/s00415-012-6628-x
- 100 Sasso E, Perucca E, Calzetti S. Double-blind comparison of primidone and phenobarbital in essential tremor. *Neurology* 1988;38:808-10. doi:10.1212/WNL.38.5.808
- 101 Koller WC. Dose-response relationship of propranolol in the treatment of essential tremor. *Arch Neurol* 1986;43:42-3. doi:10.1001/archneur.1986.00520010038018
- 102 Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. *Mov Disord* 2000;15:678-82. doi:10.1002/1531-8257(200007)15:4<678::AID-MDS1012>3.0.CO;2-0
- 103 Mohammed N, Patra D, Nanda A. A meta-analysis of outcomes and complications of magnetic resonance-guided focused ultrasound in the treatment of essential tremor. *Neurosurg Focus* 2018;44:E4. doi:10.3171/2017.11.FOCUS17628
- 104 Fishman PS, Elias WJ, Ghanouni P, et al. Neurological adverse event profile of magnetic resonance imaging-guided focused ultrasound thalamotomy for essential tremor. *Mov Disord* 2018;33:843-7. doi:10.1002/mds.27401
- 105 Dupont E, Hansen HJ, Dalby MA. Treatment of benign essential tremor with propranolol. A controlled clinical trial. *Acta Neurol Scand* 1973;49:75-84. doi:10.1111/j.1600-0404.1973.tb01280.x
- 106 Calzetti S, Findley LJ, Perucca E, Richens A. Controlled study of metoprolol and propranolol during prolonged administration in patients with essential tremor. *J Neurol Neurosurg Psychiatry* 1982;45:893-7. doi:10.1136/jnnp.45.10.893
- 107 Baruzzi A, Proccaccianti G, Martinelli P, et al. Phenobarbital and propranolol in essential tremor: a double-blind controlled clinical trial. *Neurology* 1983;33:296-300. doi:10.1212/WNL.33.3.296
- 108 Koller WC, Biary N. Metoprolol compared with propranolol in the treatment of essential tremor. *Arch Neurol* 1984;41:171-2. doi:10.1001/archneur.1984.04050140069026
- 109 Gorman WP, Cooper R, Pocock P, Campbell MJ. A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis. *J Neurol Neurosurg Psychiatry* 1986;49:64-8. doi:10.1136/jnnp.49.1.64
- 110 Cleaves L, Findley LJ. Propranolol and propranolol-LA in essential tremor: a double blind comparative study. *J Neurol Neurosurg Psychiatry* 1988;51:379-84. doi:10.1136/jnnp.51.3.379
- 111 Mally J, Stone TW. Efficacy of an adenosine antagonist, theophylline, in essential tremor: comparison with placebo and propranolol. *J Neurol Sci* 1995;132:129-32. doi:10.1016/0022-510X(95)00128-0
- 112 Gironell A, Kulisevsky J, Barbanjo M, L opez-Villegas D, Hern andez G, Pascual-Sedano B. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. *Arch Neurol* 1999;56:475-80. doi:10.1001/archneur.56.4.475
- 113 Yetimallar Y, Irtman G, Kurt T, Ba o lu M. Olanzapine versus propranolol in essential tremor. *Clin Neurol Neurosurg* 2005;108:32-5. doi:10.1016/j.clineuro.2005.01.002
- 114 Justicz N, Hapner ER, Josephs JS, Boone BC, Jinnah HA, Johns MM3rd. Comparative effectiveness of propranolol and botulinum for the treatment of essential voice tremor. *Laryngoscope* 2016;126:113-7. doi:10.1002/lary.25485
- 115 Paparella G, Ferrazzano G, Cannavacciuolo A, et al. Differential effects of propranolol on head and upper limb tremor in patients with essential tremor and dystonia. *J Neurol* 2018;265:2695-703. doi:10.1007/s00415-018-9052-z
- 116 Koller WC. Long-acting propranolol in essential tremor. *Neurology* 1985;35:108-10. doi:10.1212/WNL.35.1.108
- 117 Koller WC, Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. *Neurology* 1989;39:1587-8. doi:10.1212/WNL.39.12.1587
- 118 Calzetti S, Sasso E, Baratti M, Fava R. Clinical and computer-based assessment of long-term therapeutic efficacy of propranolol in essential tremor. *Acta Neurol Scand* 1990;81:392-6. doi:10.1111/j.1600-0404.1990.tb00982.x
- 119 Larsen TA, Ter av inen H, Calne DB. Atenolol vs. propranolol in essential tremor. A controlled, quantitative study. *Acta Neurol Scand* 1982;66:547-54. doi:10.1111/j.1600-0404.1982.tb03141.x
- 120 Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. *Am J Cardiol* 1999;83(2A):1A-38A.
- 121 Lee KS, Kim JS, Kim JW, Lee WY, Jeon BS, Kim D. A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor. *Parkinsonism Relat Disord* 2003;9:341-7. doi:10.1016/S1353-8020(03)00029-4
- 122 Leigh PN, Jefferson D, Twomey A, Marsden CD. Beta-adrenoreceptor mechanisms in essential tremor: a double-blind placebo controlled trial of metoprolol, sotalol and atenolol. *J Neurol Neurosurg Psychiatry* 1983;46:710-5. doi:10.1136/jnnp.46.8.710
- 123 Koller WC. Nadolol in essential tremor. *Neurology* 1983;33:1076-7. doi:10.1212/WNL.33.8.1076
- 124 Dietrichson P, Espen E. Primidone and propranolol in essential tremor: a study based on quantitative tremor recording and plasma anticonvulsant levels. *Acta Neurol Scand* 1987;75:332-40. doi:10.1111/j.1600-0404.1987.tb05455.x
- 125 Serrano-Due nas M. Use of primidone in low doses (250 mg/day) versus high doses (750 mg/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up. *Parkinsonism Relat Disord* 2003;10:29-33. doi:10.1016/S1353-8020(03)00070-1
- 126 Sasso E, Perucca E, Fava R, Calzetti S. Primidone in the long-term treatment of essential tremor: a prospective study with computerized quantitative analysis. *Clin Neuropharmacol* 1990;13:67-76. doi:10.1097/0002826-199002000-00007

- 127 Findley LJ, Clevees L, Calzetti S. Primidone in essential tremor of the hands and head: a double blind controlled clinical study. *J Neurol Neurosurg Psychiatry* 1985;48:911-5. doi:10.1136/jnnp.48.9.911
- 128 Sasso E, Perucca E, Fava R, Calzetti S. Quantitative comparison of barbiturates in essential hand and head tremor. *Mov Disord* 1991;6:65-8. doi:10.1002/mds.870060112
- 129 Nida A, Alston J, Schweinfurth J. Primidone Therapy for Essential Vocal Tremor. *JAMA Otolaryngol Head Neck Surg* 2016;142:117-21. doi:10.1001/jamaoto.2015.2849
- 130 Ondo WG, Jankovic J, Connor GS, et al. Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double-blind, placebo-controlled trial. *Neurology* 2006;66:672-7. doi:10.1212/01.wnl.0000200779.03748.0f
- 131 Chang KH, Wang SH, Chi CC. Efficacy and Safety of Topiramate for Essential Tremor: A Meta-Analysis of Randomized Controlled Trials. *Medicine (Baltimore)* 2015;94:e1809. doi:10.1097/MD.0000000000001809
- 132 Connor GS, Edwards K, Tarsy D. Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials. *Clin Neuropharmacol* 2008;31:97-103. doi:10.1097/WNF.0b013e3180d09969
- 133 Huber SJ, Paulson GW. Efficacy of alprazolam for essential tremor. *Neurology* 1988;38:241-3. doi:10.1212/WNL.38.2.241
- 134 Gunal DI, Afşar N, Bekiroglu N, Aktan S. New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide. *Neurol Sci* 2000;21:315-7. doi:10.1007/s100720070069
- 135 Thompson C, Lang A, Parkes JD, Marsden CD. A double-blind trial of clonazepam in benign essential tremor. *Clin Neuropharmacol* 1984;7:83-8. doi:10.1097/00002826-198403000-00004
- 136 Biary N, Koller W. Kinetic predominant essential tremor: successful treatment with clonazepam. *Neurology* 1987;37:471-4. doi:10.1212/WNL.37.3.471
- 137 Bruno E, Nicoletti A, Filippini G, Quattrocchi G, Colosimo C, Zappia M. Zonisamide for essential tremor. *Cochrane Database Syst Rev* 2017;8:CD009684.
- 138 Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. *Mov Disord* 2007;22:279-82. doi:10.1002/mds.21282
- 139 Handforth A, Martin FC, Kang GA, Vanek Z. Zonisamide for essential tremor: an evaluator-blinded study. *Mov Disord* 2009;24:437-40. doi:10.1002/mds.22418
- 140 Yetimalar Y, Irtman G, Gürgör N, Başoğlu M. Olanzapine efficacy in the treatment of essential tremor. *Eur J Neurol* 2003;10:79-82. doi:10.1046/j.1468-1331.2003.00534.x
- 141 Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. *Acta Neurol Scand* 1986;73:295-7. doi:10.1111/j.1600-0404.1986.tb03279.x
- 142 Ceravolo R, Salvetti S, Piccini P, Lucetti C, Gambaccini G, Bonuccelli U. Acute and chronic effects of clozapine in essential tremor. *Mov Disord* 1999;14:468-72. doi:10.1002/1531-8257(199905)14:3<468::AID-MDS1013>3.0.CO;2-M
- 143 Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. *Mov Disord* 1996;11:250-6. doi:10.1002/mds.870110306
- 144 Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. *Neurology* 2001;56:1523-8. doi:10.1212/WNL.56.11.1523
- 145 Rahimi F, Debicki D, Roberts-South A, Bee C, Bapat P, Jog M. Dynamic decomposition of motion in essential and parkinsonian tremor. *Can J Neurol Sci* 2015;42:116-24. doi:10.1017/cjn.2015.12
- 146 Pacchetti C, Mancini F, Bulgheroni M, et al. Botulinum toxin treatment for functional disability induced by essential tremor. *Neurol Sci* 2000;21:349-53. doi:10.1007/s100720070049
- 147 Samotus O, Kumar N, Rizek P, Jog M. Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics. *Can J Neurol Sci* 2018;45:11-22. doi:10.1017/cjn.2017.260
- 148 Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach. *Parkinsonism Relat Disord* 2018;56:65-9. doi:10.1016/j.parkreldis.2018.06.019
- 149 Pahwa R, Busenbark K, Swanson-Hyland EF, et al. Botulinum toxin treatment of essential head tremor. *Neurology* 1995;45:822-4. doi:10.1212/WNL.45.4.822
- 150 Hertegård S, Granqvist S, Lindestad PA. Botulinum toxin injections for essential voice tremor. *Ann Otol Rhinol Laryngol* 2000;109:204-9. doi:10.1177/000348940010900216
- 151 Warrick P, Dromey C, Irish JC, Durkin L, Pakiam A, Lang A. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. *Laryngoscope* 2000;110:1366-74. doi:10.1097/00005537-200008000-00028
- 152 Gurey LE, Sinclair CF, Blitzler A. A new paradigm for the management of essential vocal tremor with botulinum toxin. *Laryngoscope* 2013;123:2497-501. doi:10.1002/lary.24073
- 153 Estes C, Sadoughi B, Coleman R, Sarva H, Mauzer E, Sulica L. A prospective crossover trial of botulinum toxin chemodenervation versus injection augmentation for essential voice tremor. *Laryngoscope* 2018;128:437-46. doi:10.1002/lary.26911
- 154 Lee JY, Kondziolka D. Thalamic deep brain stimulation for management of essential tremor. *J Neurosurg* 2005;103:400-3. doi:10.3171/jns.2005.103.3.0400
- 155 Benabid AL, Pollak P, Gao D, et al. Chronic electrical stimulation of the ventralis intermedialis nucleus of the thalamus as a treatment of movement disorders. *J Neurosurg* 1996;84:203-14. doi:10.3171/jns.1996.84.2.0203
- 156 Koller W, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. *Ann Neurol* 1997;42:292-9. doi:10.1002/ana.410420304
- 157 Graff-Radford J, Foote KD, Mikos AE, et al. Mood and motor effects of thalamic deep brain stimulation surgery for essential tremor. *Eur J Neurol* 2010;17:1040-6. doi:10.1111/j.1468-1331.2010.02958.x
- 158 Nazzaro JM, Pahwa R, Lyons KE. Long-term benefits in quality of life after unilateral thalamic deep brain stimulation for essential tremor. *J Neurosurg* 2012;117:156-61. doi:10.3171/2012.3.JNS112316
- 159 Cury RG, Fraix V, Castrioto A, et al. Thalamic deep brain stimulation for tremor in Parkinson disease, essential tremor, and dystonia. *Neurology* 2017;89:1416-23. doi:10.1212/WNL.0000000000004295
- 160 Carpenter MA, Pahwa R, Miyawaki KL, Wilkinson SB, Searl JP, Koller WC. Reduction in voice tremor under thalamic stimulation. *Neurology* 1998;50:796-8. doi:10.1212/WNL.50.3.796
- 161 Obwegeser AA, Uitti RJ, Turk MF, Strongosky AJ, Wharen RE. Thalamic stimulation for the treatment of midline tremors in essential tremor patients. *Neurology* 2000;54:2342-4. doi:10.1212/WNL.54.12.2342
- 162 Sydow O, Thobois S, Alesch F, Speelman JD. Multicentre European study of thalamic stimulation in essential tremor: a six year follow up. *J Neurol Neurosurg Psychiatry* 2003;74:1387-91. doi:10.1136/jnnp.74.10.1387
- 163 Sandvik U, Koskinen LO, Lundquist A, Blomstedt P. Thalamic and subthalamic deep brain stimulation for essential tremor: where is the optimal target? *Neurosurgery* 2012;70:840-5, discussion 845-6. doi:10.1227/NEU.0b013e31818236a809
- 164 Plaha P, Javed S, Agombar D, et al. Bilateral caudal zona incerta nucleus stimulation for essential tremor: outcome and quality of life. *J Neurol Neurosurg Psychiatry* 2011;82:899-904. doi:10.1136/jnnp.2010.222992
- 165 Elias WJ, Huss D, Voss T, et al. A pilot study of focused ultrasound thalamotomy for essential tremor. *N Engl J Med* 2013;369:640-8. doi:10.1056/NEJMoa1300962
- 166 Lipsman N, Schwartz ML, Huang Y, et al. MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study. *Lancet Neurol* 2013;12:462-8. doi:10.1016/S1474-4422(13)70048-6
- 167 Chang WS, Jung HH, Kweon EJ, Zadicario E, Rachmilevitch I, Chang JW. Unilateral magnetic resonance guided focused ultrasound thalamotomy for essential tremor: practices and clinicoradiological outcomes. *J Neurol Neurosurg Psychiatry* 2015;86:257-64. doi:10.1136/jnnp-2014-307642
- 168 Elias WJ. A Trial of Focused Ultrasound Thalamotomy for Essential Tremor. *N Engl J Med* 2016;375:2202-3. doi:10.1056/NEJMoa1600159
- 169 Meng Y, Solomon B, Boutet A, et al. Magnetic resonance-guided focused ultrasound thalamotomy for treatment of essential tremor: A 2-year outcome study. *Mov Disord* 2018;33:1647-50. doi:10.1002/mds.99
- 170 Chang JW, Park CK, Lipsman N, et al. A prospective trial of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor: Results at the 2-year follow-up. *Ann Neurol* 2018;83:107-14. doi:10.1002/ana.25126
- 171 Boutet A, Ranjan M, Zhong J, et al. Focused ultrasound thalamotomy location determines clinical benefits in patients with essential tremor. *Brain* 2018;141:3405-14.
- 172 Tian Q, Wintermark M, Jeffrey Elias W, et al. Diffusion MRI tractography for improved transcranial MRI-guided focused ultrasound thalamotomy targeting for essential tremor. *Neuroimage Clin* 2018;19:572-80. doi:10.1016/j.nicl.2018.05.010
- 173 Krishna V, Sannmartino F, Agrawal P, et al. Prospective Tractography-Based Targeting for Improved Safety of Focused Ultrasound Thalamotomy. *Neurosurgery* 2019;84:160-8.
- 174 Iacopino DG, Gagliardo C, Giugno A, et al. Preliminary experience with a transcranial magnetic resonance-guided focused ultrasound surgery system integrated with a 1.5-T MRI unit in a series of patients with essential tremor and Parkinson's disease. *Neurosurg Focus* 2018;44:E7. doi:10.3171/2017.11.FOCUS17614

- 175 Pathak A, Redmond JA, Allen M, Chou KL. A noninvasive handheld assistive device to accommodate essential tremor: a pilot study. *Mov Disord* 2014;29:838-42. doi:10.1002/mds.25796
- 176 Haubenberger D, McCrossin G, Lungu C, et al. Octanoic acid in alcohol-responsive essential tremor: a randomized controlled study. *Neurology* 2013;80:933-40. doi:10.1212/WNL.0b013e3182840c4f
- 177 Voller B, Lines E, McCrossin G, et al. Dose-escalation study of octanoic acid in patients with essential tremor. *J Clin Invest* 2016;126:1451-7. doi:10.1172/JCI83621
- 178 Gironell A, Pascual-Sedano B, Marín-Lahoz J. Perampanel, a new hope for Essential tremor: An open label trial. *Parkinsonism Relat Disord* 2019;60:171-2. doi:10.1016/j.parkreldis.2018.10.010
- 179 Lin PT, Ross EK, Chidester P, et al. Noninvasive neuromodulation in essential tremor demonstrates relief in a sham-controlled pilot trial. *Mov Disord* 2018;33:1182-3. doi:10.1002/mds.27350

Appendix Patient video